Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2007

01-05-2007 | Original Article

Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer

Authors: G. Mangili, M. Picchio, S. Sironi, R. Viganò, E. Rabaiotti, D. Bornaghi, V. Bettinardi, C. Crivellaro, C. Messa, F. Fazio

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2007

Login to get access

Abstract

Purpose

The aims of this study were to compare CT with PET/CT results in patients with suspected ovarian cancer recurrence and to assess the impact of the PET/CT findings on their clinical management.

Methods

Thirty-two consecutive patients with suspected ovarian cancer recurrence were retrospectively included in the study. Abdominal contrast-enhanced CT and PET/CT with [18F]FDG, in addition to conventional follow-up, were performed in all 32 patients. After the comparison between CT and PET/CT results, based on clinical reports, changes in the clinical management of patients (intermodality changes) due to PET/CT information were analysed.

Results

Twenty of the 32 patients were positive at CT (62.5%) versus 29 (90.6%) at PET/CT. Intermodality changes in management, i.e. use of a different treatment modality, after PET/CT examination were indicated in 14/32 (44%) patients. In particular, before PET/CT study, the planned management was as follows: wait-and-see in 7/32 (22%), further instrumental examinations in 4/32 (12%), chemotherapy in 10/32 (31%), diagnostic surgical treatment in 6/32 (19%) and surgical treatment in the remaining 5/32 (16%). After PET/CT study, wait-and-see was indicated in 1/32 (3%), further instrumental examinations in 7/32 (22%), chemotherapy in 16/32 (50%), diagnostic surgical treatment in 2/32 (6%) and surgical treatment in the remaining 6/32 (19%).

Conclusion

Integrated PET/CT could detect tumour relapse in a higher percentage of patients than could CT. A change in the clinical management was observed in 44% of cases when PET/CT information was added to conventional follow-up findings.
Literature
1.
Greenlee RT, Hill Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15–36.CrossRefPubMed
2.
Ries LAG, Miller BA, Hankey BF. SEER cancer statistics review, 1973–1991. National Cancer Institute. NIH Publ. 1997;94:2789.
3.
Topuz E, Aydiner A, Saip P, Eralp Y, Tas F, Salihoglu Y, et al. Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer. Eur J Gynaecol Oncol. 2000;21:599–602.PubMed
4.
Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Rath W, et al. 2-Fluorine]-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83:310–5.CrossRefPubMed
5.
6.
Picchio M, Sironi S, Messa C, Mangili G, Landoni C, Gianolli L, et al. Advanced ovarian carcinoma: usefulness of [18F]FDG-PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med. 2003;47:77–84.PubMed
7.
Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol. 2001;176:1449–54.CrossRefPubMed
8.
Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshkawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 2002;29:797–803.CrossRefPubMed
9.
Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369–79.PubMed
10.
Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002;225:575–81.CrossRefPubMed
11.
Casey J. Colonography and tumor staging during single-session PET/CT. Nature Clinical Practice Gastroenterology Hepatology 2006;3:184–5.CrossRef
12.
Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Hojgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005;32:1167–75.CrossRefPubMed
13.
Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garavaglia E, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 2004;233:433–40.CrossRefPubMed
14.
Kurtz AB, Tsimikas JV, Tempany CM, Hamper U, Arger PH, Bree RL, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis. Report of the Radiology Diagnostic Oncology Group. Radiology 1999;212:19–27.CrossRefPubMed
15.
Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities—report from the Radiological Diagnostic Oncology Group. Radiology 2000;215:761–7.CrossRefPubMed
16.
Kubik-Huch RA, Dorffler W, von Schulthess GK, Marincek B, Kochli OR, Seifert B, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761–7.CrossRefPubMed
17.
Ak I, Stokkel MP, Pauwels EK. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 2000;126:560–74.CrossRefPubMed
18.
Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001;82:17–21.CrossRefPubMed
19.
Drieskens O, Stroobants S, Gysen M, Vandenbosch G, Mortelmans L, Vergote I. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol Obstet Invest 2003;55:130–4.CrossRefPubMed
20.
Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynaecol Oncol 2005;97:183–91.CrossRef
21.
Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914–24.CrossRefPubMed
22.
Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177–89.PubMed
23.
Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, et al. The impact of PET on the management of lung cancer: the referring physician’s perspective. J Nucl Med 2002;43:752–6.PubMed
24.
Smith GT, Hubner KF, McDonald T, Thie JA. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Positron Imaging 1999;2:63–70.CrossRefPubMed
25.
Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42(Suppl 5):1–93.
26.
Hillner BE, Tunuguntla R, Fratkin M. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol 2004;22:4147–56.CrossRefPubMed
27.
Pepe G, Rossetti C, Sironi S, Landoni C, Gianolli L, Pastorino U, et al. Patients with known or suspected lung cancer: evaluation of clinical management changes due to FDG PET study. Nucl Med Commun 2005;26:831–7.CrossRefPubMed
28.
Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254–61.CrossRefPubMed
29.
Herder GJ, Van Tinteren H, Comans EF, Hoekstra OS, Teule GJ, Postmus PE, et al. Prospective use of serial questionnaires to evaluate the therapeutic efficacy of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer. Thorax 2003;58:47–51.CrossRefPubMedPubMedCentral
30.
Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, et al. Clinical impact of 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001;19:111–8.CrossRefPubMed
31.
van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388–93.CrossRefPubMed
32.
MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287–93.CrossRefPubMed
33.
Meta J, Seltzer M, Schiepers C, Silverman DH, Ariannejad M, Gambhir SS, et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician’s perspective. J Nucl Med 2001;42:586–90.PubMed
34.
Ruiz-Hernandez G, Delgado-Bolton RC, Fernandez-Perez C, Lapena L, Jimenez-Vicioso A, Perez-Castejon MJ, et al. Impact of positron emission tomography with FDG-PET in treatment of patients with suspected recurrent ovarian cancer. Rev Esp Med Nucl 2005;24:113–26.CrossRefPubMed
Metadata
Title
Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer
Authors
G. Mangili
M. Picchio
S. Sironi
R. Viganò
E. Rabaiotti
D. Bornaghi
V. Bettinardi
C. Crivellaro
C. Messa
F. Fazio
Publication date
01-05-2007
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2007
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-006-0306-0

Other articles of this Issue 5/2007

European Journal of Nuclear Medicine and Molecular Imaging 5/2007 Go to the issue

Original article

Indium-111 oxine labelling affects the cellular integrity of haematopoietic progenitor cells

Image of the month

Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation

Book review

International Atomic Energy Agency: Nuclear medicine resources manual. 2006. IAEA, Vienna, 532 pp., 55 illustrations. €65.00. ISBN 92-0-107504-9.

Original article

The incremental value of 18F-FDG PET/CT in paediatric malignancies

Review article

Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”

Special contribution

The new EANM paediatric dosage card